Institutional shares held 122 Million
1.18M calls
64.6K puts
Total value of holdings $2.87B
$27.6M calls
$1.52M puts
Market Cap $4.4B
187,404,992 Shares Out.
Institutional ownership 65.23%
# of Institutions 161


Latest Institutional Activity in NKTR

Top Purchases

Q2 2025
Rise Advisors, LLC Shares Held: 49 ($1.15K)
Q2 2025
Nova Wealth Management, Inc. Shares Held: 10 ($235)
Q1 2025
Almitas Capital LLC Shares Held: 4.61M ($108M)
Q1 2025
Aqr Capital Management LLC Shares Held: 3.64M ($85.5M)
Q1 2025
Exome Asset Management LLC Shares Held: 2.23M ($52.4M)

Top Sells

Q2 2025
Parallel Advisors, LLC Shares Held: 1.05K ($24.7K)
Q1 2025
Millennium Management LLC Shares Held: 2.29M ($53.7M)
Q1 2025
Altium Capital Management LP Shares Held: 1.05M ($24.7M)
Q1 2025
Ubs Oconnor LLC Shares Held: 19.9K ($468K)
Q1 2025
Woodline Partners LP Shares Held: 3.69M ($86.6M)

About NKTR

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.


Insider Transactions at NKTR

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
712K Shares
From 3 Insiders
Grant, award, or other acquisition 712K shares
Sell / Disposition
380K Shares
From 3 Insiders
Open market or private sale 380K shares

Track Institutional and Insider Activities on NKTR

Follow NEKTAR THERAPEUTICS and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NKTR shares.

Notify only if

Insider Trading

Get notified when an Nektar Therapeutics insider buys or sells NKTR shares.

Notify only if

News

Receive news related to NEKTAR THERAPEUTICS

Track Activities on NKTR